Form 4 for BMRN BIOMARIN PHARMACEUTICAL INC
Accepted 2025-03-18 00:00:00 ET · period of report 2025-03-14 · accession 0001048477-25-000027 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-18 | 2025-03-14 | BMRN | Hardy Alexander | CEO, Dir | F - Tax | $69.44 | -2,933 | 131.2K | -2% | -$203.7K |
| D | 2025-03-18 | 2025-03-17 | BMRN | Hardy Alexander | CEO, Dir | A - Grant | $0.00 | +44.4K | 175.6K | +34% | $0 |
| D | 2025-03-18 | 2025-03-17 | BMRN | Hardy Alexander | CEO, Dir | A - Grant | $0.00 | +61.8K | 61.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-14 | F | D | 2,933 | $69.44 | 131,223 | D | — | — | |
| 2 | Common | Common Stock | 2025-03-17 | A | A | 44,360 | $0.00 | 175,583 | D | — | — | (F1) Restricted stock units granted March 17, 2025. Price not applicable. |
| 3 | Derivative | Stock Option (Right to Buy Common Stock) | 2025-03-17 | A | A | 61,750 | $0.00 | 61,750 | D | $71.55 · 2026-03-17 to 2035-03-16 | 61,750 Common Stock | (F2) Option grant vests 12/48th on March 17, 2026 and 1/48th on the 17th day of each month thereafter. |